least
million
acute
case
malaria
year
globally
resulting
million
death
ninety
percent
death
due
malaria
occur
africa
south
sahara
mostly
young
child
number
death
increasing
one
key
factor
linked
widespread
drug
resistance
plasmodium
falciparum
conventional
antimalarial
sp
resistance
widespread
southeast
asia
south
america
africa
inappropriate
use
antimalarial
past
century
contributed
increase
resistance
example
overreliance
quinolines
chloroquine
antifolates
pyrimethamine
resulting
among
drug
class
however
past
decade
new
group
artemisinin
compound
artesunate
artemether
deployed
increasingly
large
scale
compound
produce
rapid
therapeutic
response
active
parasite
resistant
multiple
drug
well
tolerated
reduce
gametocyte
carriage
date
parasite
resistance
compound
detected
used
alone
artemisinins
cure
falciparum
malaria
seven
day
study
southeast
asia
shown
combination
artemisinin
compound
certain
synthetic
drug
produce
high
cure
rate
three
day
treatment
also
evidence
combination
therapy
could
greatly
retard
development
resistance
partner
drug
although
combination
including
artemisinins
widely
advocated
expensive
relatively
untested
highly
endemic
area
month
plo
medicine
adoke
yeka
colleague
compared
compound
combination
therapy
four
district
varying
transmission
intensity
uganda
patient
aged
six
month
greater
uncomplicated
falciparum
malaria
team
tested
combination
chloroquine
sp
currently
therapy
uganda
combination
amodiaquine
sp
cheap
regimen
proven
efficacious
previous
trial
combination
amodiaquine
artesunate
study
collected
data
efficacy
different
regimen
examined
effect
recrudescence
new
infection
therapy
combined
amodiaquine
artesunate
efficacious
regimen
preventing
recrudescence
benefit
outweighed
increased
risk
new
infection
result
probably
due
artesunate
rapidly
eliminated
leaving
amodiaquine
provide
prophylaxis
considering
recurrent
infection
combination
amodiaquine
sp
least
efficacious
combination
site
superior
highest
transmission
site
recurrent
infection
due
new
infection
two
efficacious
regimen
amodiaquine
sp
amodiaquine
artesunate
proportion
identification
new
infection
stressed
need
malaria
control
measure
bed
net
said
author
also
suggested
antimalarial
judged
impact
recrudescence
also
impact
risk
new
infection
therapy
previous
study
suggested
patient
suffer
recrudescence
higher
risk
complicated
malaria
death
artemisinins
highly
attractive
antimalarial
used
monotherapy
high
risk
recrudescence
hence
must
combined
antimalarial
achieve
maximum
efficacy
whether
partner
drug
long
short
acting
remains
unclear
said
author
altogether
artemisinin
combination
offer
great
hope
africa
author
say
although
ideal
combination
regimen
remains
uncertain
cost
problem
compare
efficacy
different
therapy
bigger
longer
controlled
trial
needed
condition
varied
transmission
intensity
nevertheless
based
result
study
others
uganda
chosen
combination
artemether
lumefantrine
therapy
malaria